for immediate release
March 6, 2025 08:00 a.m. Mountain Standard Time
TUCSON A.Z. – UGenome AI, a pioneer in genomic platforms to fuel personalized medicine, today announced the release of ProPEx, a fast, affordable, and comprehensive pharmacogenomic analysis tool for small to medium sized genetic testing labs, services, and counseling companies that requires no technical expertise. ProPEx offers an alternative solution to the often expensive, slow, or limited gene coverage of other solutions on the market, giving companies a way to more effectively determine an individual’s drug response status. In particular, small to mid-scale genetic testing companies that have historically struggled with cost barriers and the complexity of prior tools can benefit from ProPEx.
ProPEx offers a broader pharmacogenomic profile than many genomics tools, covering 86 genes, including 22 actionable genes based on FDA, CPIC, and DPWG guidelines. The platform was also validated with the 1000 Genomes Project database, leveraging resources like PharmVar and PharmGKB. Further, ProPEx provides rapid analysis, enabling faster turnaround times of just 20-30 minutes for a whole genome sequence. Due to ProPEx’s simple load and fetch file to download the report function, ProPEx makes pharmacogenomic interpretation accessible to genetic testing companies with limited bioinformatics expertise. Also, with a lower price point per run, ProPEx offers an affordable option, making advanced pharmacogenomics feasible for smaller genetic testing companies.
“The release of ProPEx will empower genetic testing companies to offer comprehensive pharmacogenomic insights without high costs or complex setups and additional sample collection that historically proved a barrier to entry for them in the pharmacogenomic space,” said Zachary Brooks, PhD, founder and CEO of UGenome AI. “With ProPEx, our customers can gain access to broader and faster pharmacogenomic analyses, facilitating advancements in precision medicine and making a direct impact on patients’ lives.”
ProPEx seamlessly integrates into existing next-generation sequencing workflows. In addition, ProPEx enables genetic testing companies to extract valuable PGx data without the need for additional samples or complex test development.
“With ProPEx, genetic testing companies can get wider gene coverage of up to 86 genes or elect for 22 guideline-associated genes. Our pharmacogenetic reports help clinicians make more informed decisions about a patient’s drug response status,” said Jayden Lee, EMBA, PharmD, Chief Genomics Officer of UGenome AI. “ProPEx can support delivering personalized medicine plans for patients, helping them reduce adverse drug reactions and improve treatment outcomes.”
####
About UGenome AI
UGenome AI is a startup biotech company focusing on developing genomics software. UGenome AI is advancing genomics analysis and helping patients receive personalized care, faster. Our products stem from our personalized reference genome and pharmacogenomics tools to help patients receive personalized treatments within weeks, not years. For more information, please visit www.ugenome.bio.
Contacts
For UGenome AI Inquiries:
Zachary Brooks
For Media:
Emma Bardin